Matched-Pair Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy.
Where this comes from
- Record sourced from PubMed, PMID 31253741.
- Also identified by DOI 10.2967/jnumed.119.229187 and PMC identifier 6954457.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<sup>18</sup>F-labeled prostate-specific membrane antigen (PSMA)-ligand PET has several principal advantages over <sup>68</sup>Ga-PSMA-11. The purpose of this retrospective study was to evaluate the frequency of non-tumor-related uptake and the detection efficacy comparing <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT in recurrent prostate cancer (PC) patients. <b>Methods:</b> The study included 102 patients with biochemically recurrent PC after radical prostatectomy undergoing <sup>18</sup>F-PSMA-1007 PET/CT imaging. On the basis of various clinical variables, patients with corresponding <sup>68</sup>Ga-PSMA-11 PET/CT scans were matched. All PET/CT scans (<i>n</i> = 204) were reviewed by 1 nuclear medicine physician. First, all PET-positive lesions were noted. Then, lesions suspected of being recurrent PC were differentiated from lesions attributed to a benign origin on the basis of known pitfalls and information from CT. For each region, the SUV<sub>max</sub> of the lesion with the highest PSMA-ligand uptake was noted. Detection rates were determined, and SUV<sub>max</sub> was compared separately for <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-PSMA-1007. <b>Results:</b> In total, <sup>18</sup>F-PSMA-1007 PET and <sup>68</sup>Ga-PSMA-11 PET revealed 369 and 178 PSMA-ligand-positive lesions, respectively. <sup>18</sup>F-PSMA-1007 PET revealed approximately 5 times more lesions attributed to a benign origin than did <sup>68</sup>Ga-PSMA-11 PET (245 vs. 52 lesions, respectively). The benign lesions most frequently observed were ganglia, unspecific lymph node, and bone lesions, at a rate of 43%, 31%, and 24% for <sup>18</sup>F-PSMA-1007 PET and 29%, 42%, and 27% for <sup>68</sup>Ga-PSMA-11 PET, respectively. The SUV<sub>max</sub> of lesions attributed to a benign origin was significantly higher (<i>P</i> < 0.0001) for <sup>18</sup>F-PSMA-1007 PET. Further, a similar number of lesions was attributed to recurrent PC (124/369 for <sup>18</sup>F-PSMA-1007 PET and 126/178 for <sup>68</sup>Ga-PSMA-11 PET). <b>Conclusion:</b> The number of lesions with increased PSMA-ligand uptake attributed to a benign origin is considerably higher for <sup>18</sup>F-PSMA-1007 PET than for <sup>68</sup>Ga-PSMA-11 PET. This finding indicates the need for sophisticated reader training emphasizing known pitfalls and reporting within the clinical context.
Medical subject headings
- Gallium Radioisotopes
- Membrane Glycoproteins
- Niacinamide
- Oligopeptides
- Organometallic Compounds
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms